Crossmark

Fluorescence lifetime imaging ophthalmoscopy (FLIO) of patients with neovascular age-related macular degeneration before and after treatment with intravitreal ranibizumab

Crossref DOI link: https://doi.org/10.1007/s00417-025-07103-1

Published Online: 2026-01-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sonntag, Svenja Rebecca

Fries, Stella

Gniesmer, Stefanie

Grisanti, Salvatore

Miura, Yoko
Funding

Funding for this research was provided by:

Universität zu Lübeck
License Information

Text and Data Mining valid from 2026-01-20

Version of Record valid from 2026-01-20
More Information

Article History

Received: 9 October 2025

Revised: 23 December 2025

Accepted: 25 December 2025

First Online: 20 January 2026

Declarations

:

: The study was positively reviewed by the Institutional Review Board of the University of Lübeck in Germany and the study protocol was conducted in accordance with the Declaration of Helsinki. Written informed consent was performed prior to study inclusion.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below